Last updated: February 24, 2026
What is NDC 31722-0103?
NDC 31722-0103 refers to a specific drug product. It is marketed as Anifrolumab, a monoclonal antibody used to treat systemic lupus erythematosus (SLE). Approved by the U.S. Food and Drug Administration (FDA) in August 2021, this drug is marketed under the brand name Saphnelo.
Market Overview
Treatment Indications:
- Systemic lupus erythematosus (SLE)
- Moderate to severe cases in adult patients
Market Size:
- The global lupus drug market was valued at approximately USD 2.2 billion in 2021.
- SLE prevalence in the U.S. stands around 250,000 to 500,000 patients.
- The U.S. accounts for nearly 40% of the global pathway for SLE medications, with increasing adoption rates for biologics.
Competitive Landscape:
| Product |
Type |
Approval Year |
Annual Sales (2022) |
Key Competitors |
| Saphnelo (Anifrolumab) |
Monoclonal antibody |
2021 |
USD 160 million |
Benlysta, Rituxan, AstraZeneca's drugs |
| Benlysta (belimumab) |
Monoclonal antibody |
2011 |
USD 1.4 billion |
Rituxan, Felzartamab |
Market Penetration:
- Saphnelo's uptake remains moderate, primarily due to the high cost of biologics.
- Adoption is concentrated among academic centers and specialty clinics.
- Physicians are cautious about switching due to insurance coverage hurdles and long-term safety data.
Pricing Landscape
Current Price Point
- The average wholesale price (AWP) for Saphnelo is approximately USD 42,000 per year per patient.
- The pricing is comparable with other biologics for SLE, like Benlysta, which averages USD 35,000 to USD 50,000 per year.
Factors Influencing Pricing:
- Biologic complexity increases manufacturing costs.
- Market exclusivity extends until at least 2031.
- High development and commercialization expenses.
Reimbursement and Insurance Coverage:
- Most commercial insurers cover Saphnelo for approved indications.
- Patient out-of-pocket costs vary, with co-pays generally USD 10 to USD 50 per month.
Future Price Projections
Near-term (Next 1-3 Years)
- No significant price reductions expected, due to limited biosimilar competition.
- Price stabilization at USD 40,000 – USD 45,000 annually.
Medium-term (3-5 Years)
- Entry of biosimilars is unlikely before 2030, given patent protections and manufacturing complexities.
- Possible slight discounts or negotiated prices with payers may reduce costs by 5-10%.
Long-term (5+ Years)
- Biosimilar development may exert downward pressure, potentially reducing the price by 20%-30% if biosimilar approvals occur.
- Price decreases could align with global market trends and generic biologic competition.
Regulatory and Policy Impact
- Patent exclusivity extends until potentially 2031.
- No current biosimilars approved or in final development stages specifically for Saphnelo.
- Price regulation policies under consideration: some states in the U.S. are exploring drug price transparency laws, which could influence pricing strategies.
Risks to Market and Price Projections
- Delays in biosimilar development.
- Regulatory changes affecting patent enforcement.
- Varying insurance payor policies impacting patient access.
- Emergence of alternative therapies, including small molecule drugs, which could diversify treatment options.
Key Takeaways
- NDC 31722-0103 (Saphnelo) entered a limited but growing market for SLE biologics in 2021.
- Current price approximates USD 42,000 annually, with stable outlook over the next few years.
- Entry of biosimilars is unlikely before 2030, maintaining current pricing trends.
- Market growth is constrained by high costs, insurance hurdles, and physician familiarity.
- Long-term price decreases depend heavily on biosimilar approval and market penetration.
FAQs
1. What factors influence Saphnelo’s pricing compared to other biologics?
Pricing reflects manufacturing complexity, market exclusivity, development costs, and healthcare payor negotiations.
2. How does biosimilar development impact future prices?
Introduction of biosimilars could reduce prices by up to 30% if biosimilar versions receive approval and market penetration is successful.
3. Is Saphnelo preferred over other SLE treatments?
Physicians consider Saphnelo when patients do not respond well to or are contraindicated for Belimumab or Rituximab, but it remains a second-line biologic due to cost and familiarity.
4. What is the projected market size for Saphnelo in the next five years?
The market is expected to grow at a CAGR of 12-15%, reaching USD 500 million to USD 700 million depending on adoption rates.
5. Are there any regulatory or reimbursement changes likely to affect prices?
Potential policy shifts towards price transparency and biosimilar approval timelines could influence future cost structures.
References
- IQVIA. (2022). United States Prescription Drug Market Data.
- FDA. (2021). Approval letter for Saphnelo.
- EvaluatePharma. (2022). Global lupus market analysis.
- Centers for Disease Control and Prevention. (2022). Lupus prevalence statistics.
- Statista. (2022). Biologic drug market trends.
